

CP-1615

CASE 4-21233/A

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen G. Kalinchak
Type or print name

Stephen G. Kalinchak
Signature

1/5/00
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BURKHARD SCHLÜTERMANN
INTERNATIONAL APPLICATION NO: PCT/EP98/00794
FILED: 12 FEBRUARY 1998
U.S. APPLICATION NO: 09/367,361
35 USC §371 DATE: 11 AUGUST 1999
FOR: OXACARBAZEPINE FILM-COATED TABLETS

#5
HKO
2-3-00

JAN 14 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed before the mailing of a first Office Action on the merits. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


The following is a statement of relevance for the non-English language document:

Nurnberg et al. relates to reducing the particle size of certain materials,
including pharmaceuticals.

The Examiner is requested to consider the foregoing information in relation to this
application and indicate that each reference was considered by returning a copy of the initialed PTO
1449 form(s).

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6763



Stephen G. Kalinchak
Attorney for Applicant
Reg. No. 38,747

Date: 1/5/00